Jonathan Young

Chief Operating Officer

Jonathan Young (Chief Operating Officer) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in AKRO. The largest single filing was $597K of AKRO (12,500 sh across 2 lots, as filed), executed Oct 1 2025.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 1 sells

Median delay

–

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$597K

shares × price, as filed

Last traded

Oct 1 2025

Filed Oct 3 2025

Open performance→

Volume by month

Buys $0 Sells $8.3M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Not on file 1 filing

Sector per market data · by filing · past 12 months

Most traded names

AKRO AKRO AKRO · 0 buys · 11 sells 11 filings

Recent filings

AKROSALE Akero Therapeutics, Inc. View filing → $597K
12,500 sh across 2 lots
Exec Oct 1 2025
Filed Oct 3 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $573K
12,439 sh across 2 lots
Exec Sep 2 2025
Filed Sep 4 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $532K
11,151 sh × $47.72
Exec Aug 12 2025
Filed Aug 13 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $135K
2,493 sh × $53.99
Exec Jun 10 2025
Filed Jun 12 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $2.2M
50,000 sh across 2 lots
Exec Mar 4 2025
Filed Mar 5 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $538K
10,000 sh across 2 lots
Exec Feb 3 2025
Filed Feb 5 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $280K
10,000 sh × $28.03
Exec Jan 2 2025
Filed Jan 6 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $321K
10,000 sh × $32.13
Exec Dec 2 2024
Filed Dec 4 2024 · 5:30 PM ET More filings →